Lymphoma is classified as a blood cancer, not a solid tumor, even though it routinely forms firm, palpable masses in lymph nodes and organs. This confuses a lot of people, and understandably so. A lump you can feel or see on imaging looks like a solid tumor, yet oncologists group lymphoma alongside leukemia and myeloma under “hematological malignancies.” The reason comes down to origin: lymphoma arises from lymphocytes, a type of white blood cell, rather than from the epithelial or connective tissues that give rise to carcinomas and sarcomas. That origin story shapes nearly everything about how lymphoma is diagnosed, staged, treated, and studied in clinical trials.
Why Lymphoma Gets Mistaken for a Solid Tumor
Most blood cancers are invisible to the naked eye. Leukemia circulates in the bloodstream. Multiple myeloma lives inside bone marrow. Neither produces an obvious lump. Lymphoma breaks this pattern. It typically presents as swollen lymph nodes, sometimes painfully obvious in the neck, armpit, or groin, and can grow into large masses in the chest or abdomen. On a CT or PET scan, a lymphoma mass looks indistinguishable from a solid tumor to an untrained eye. Surgeons can hold it in their hands during a biopsy. That physical reality is why patients, and even some clinicians in casual conversation, blur the line.
The key distinction is cellular. Solid tumors originate from organ tissues: breast epithelium, colon lining, lung cells, bone, or connective tissue. Lymphoma originates from lymphocytes, specifically from the machinery those cells use to build and diversify antibodies. B cells are especially vulnerable to malignant transformation because the genetic rearrangements they undergo to create diverse antibodies can go wrong, producing chromosomal translocations and cancer-driving mutations.1PubMed Central. Pathogenesis of human B cell lymphomas Despite growing into tumor-like masses, lymphoma cells retain the identity and behavior of blood cells. They travel through the lymphatic system. They can show up in the bloodstream. And they respond to therapies designed for blood cancers far better than to treatments built around solid tumor biology.
How Lymphoma Behaves Differently from Solid Tumors
Solid tumors tend to start in one spot and spread outward in a somewhat predictable fashion, first invading nearby tissue, then reaching regional lymph nodes, then metastasizing to distant organs. Lymphoma does not follow that script. Because lymphocytes normally circulate throughout the body, lymphoma can appear simultaneously in multiple lymph node groups or organs without the stepwise invasion that characterizes, say, colon cancer spreading to the liver. A person diagnosed with lymphoma may have disease in the neck, the spleen, and the bone marrow all at once, not because the cancer “metastasized” in the solid tumor sense, but because the malignant lymphocytes were already moving through a system designed to carry them everywhere.
This difference has enormous practical consequences. Solid tumors are often staged by how far they have physically spread from the primary site, with surgery to remove the original mass playing a central role. Lymphoma staging uses a modified version of the Ann Arbor system, now updated through the Lugano classification, which maps how many lymph node regions are involved and whether the disease has crossed the diaphragm or entered organs outside the lymphatic system.2PubMed Central. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification The framework looks at anatomic distribution of disease rather than the depth-of-invasion metrics used for most solid cancers.
Surgery Plays a Much Smaller Role
If you are diagnosed with a solid tumor, the first question is often “can we cut it out?” For lymphoma, that question almost never comes up. Non-Hodgkin lymphomas are treated primarily with chemotherapy, biologic therapy, radiotherapy, and stem cell transplantation because these approaches are far more effective against a cancer that is inherently systemic.3PubMed Central. Surgery for Non-Hodgkin’s Lymphoma Removing a single mass of lymphoma would do little good when the malignant cells are already distributed through the lymphatic network. Surgery in lymphoma is largely limited to obtaining a biopsy for diagnosis rather than serving as a treatment itself.
Radiation therapy does have a role in lymphoma, particularly for localized low-grade disease, but even here the pattern differs from solid tumor oncology. While local control of the irradiated area is reliably achieved, a substantial proportion of patients later relapse with disease outside the radiation field.4PubMed. Radiation therapy for localized low-grade non-Hodgkin’s lymphomas That pattern underscores lymphoma’s blood-cancer nature: even when the visible mass is eliminated locally, malignant lymphocytes may persist elsewhere. Radiation oncologists treating extranodal lymphomas have adopted volume definitions similar to those used for solid tumors, a practical borrowing of technique that does not change the underlying biology.5PubMed. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group
When Lymphoma Shows Up Outside the Lymph Nodes
About 30% of lymphomas occur in sites outside the lymph nodes, spleen, or bone marrow, and that percentage has been climbing over the past decade.6PubMed Central. Extranodal lymphoma: pathogenesis, diagnosis and treatment These extranodal lymphomas can show up in the stomach, the skin, the nasal passages, or the brain, among other places. When a lymphoma is growing inside the stomach wall or the brain, it looks, acts, and causes symptoms much like a solid tumor would in those locations. A patient with primary central nervous system lymphoma may present with neurological symptoms identical to those caused by a brain tumor. A patient with gastric MALT lymphoma may have symptoms that mimic stomach cancer.
This overlap in presentation adds to the confusion, but the cancer’s identity does not change. A lymphoma growing in the stomach is still a malignancy of lymphocytes, not of stomach lining cells. The treatment strategies reflect that: gastric MALT lymphoma, for instance, is often treated first by eradicating the Helicobacter pylori infection that triggered it, then with systemic therapy if needed, rather than with the surgical resection that would be standard for gastric adenocarcinoma. The distinction matters enormously for patients, because being treated under the wrong framework could mean receiving inappropriate therapy.
Diagnosis Borrows from Both Worlds
Diagnosing lymphoma typically requires a tissue biopsy, ideally an excisional biopsy of an entire lymph node rather than a needle sample. Pathologists examine the tissue architecture and cell morphology, run immunohistochemistry panels, and sometimes perform molecular testing to determine the lymphoma subtype. This biopsy-centered process resembles solid tumor diagnosis. But the staging workup after diagnosis relies heavily on tools tailored to blood cancers.
CT and PET/CT scans are essential for mapping the extent of disease, just as they would be for a solid tumor. However, these imaging tools have blind spots: they cannot detect early genetic changes in the cancer or identify tiny amounts of residual disease after treatment. That limitation has driven interest in circulating tumor DNA, or ctDNA, which is detected through a blood draw. Because lymphoma cells shed DNA fragments into the bloodstream, this liquid biopsy approach offers a noninvasive way to track disease that overcomes some of the challenges of deep-seated tumors that are hard to reach with a needle.7PubMed Central. Circulating tumor DNA in lymphoma: technologies and applications The fact that lymphoma sheds detectable DNA into the blood further reinforces its hematological nature.
Subtypes Are Remarkably Diverse
One reason the “solid vs. blood” question keeps coming up is that lymphoma is not one disease. There are more than 70 recognized subtypes of non-Hodgkin lymphoma alone, ranging from indolent follicular lymphoma that may not need treatment for years to aggressive diffuse large B-cell lymphoma (DLBCL) that demands immediate chemotherapy. Hodgkin lymphoma, a separate category, has its own subtypes. Each behaves differently, responds to different treatments, and carries a different prognosis.
Even within a single subtype, biology varies. DLBCL, the most common aggressive lymphoma, can be subdivided by its cell of origin into germinal center B-cell (GCB) and activated B-cell (ABC) types, among others. Patients with the GCB subtype have significantly better overall survival than those with the ABC subtype, a difference that standard pathology sometimes fails to capture but that newer molecular assays can reliably detect.8PubMed Central. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues These molecular distinctions are increasingly guiding treatment decisions and are expected to shape future clinical trials.
Viruses and Lymphoma
Some lymphomas have an infectious trigger, another feature that sets them apart from most solid tumors. The Epstein-Barr virus (EBV), discovered in African Burkitt lymphoma in 1964, has since been linked to a remarkably diverse range of lymphoma types. Because EBV naturally persists in the B cells of otherwise healthy people, it is easy to see how it could contribute to B-cell lymphomas when the normal controls on infected cells break down. But EBV is not limited to B-cell disease; it has also been found in T-cell and natural killer cell lymphomas, as well as certain epithelial cancers.1PubMed Central. Pathogenesis of human B cell lymphomas Other infections, including Helicobacter pylori (linked to gastric MALT lymphoma) and human T-cell lymphotropic virus, play roles in specific subtypes. Solid tumors can have viral drivers too, but the breadth of viral involvement across lymphoma subtypes is distinctive.
How the Classification Affects Clinical Trials
The solid-versus-blood distinction is not just academic. It directly determines how new treatments for lymphoma are tested and approved. Clinical trials for solid tumors typically measure whether a tumor shrinks or grows using a set of imaging criteria called RECIST, which evaluates changes in tumor size on scans. Lymphoma trials, by contrast, use different response criteria, most commonly the Lugano classification, which integrates PET findings and accounts for the way lymphoma disease patterns do not map cleanly onto RECIST’s solid-tumor assumptions.9Journal of Clinical Oncology. Clinical outcomes in phase I trials across solid tumors and hematological malignancies This means that a patient enrolling in a lymphoma trial will have their response measured differently than a patient with lung or breast cancer, even if both cancers formed visible masses on imaging.
The different endpoint frameworks add complexity to drug development. A treatment that looks promising in solid tumors may need to be re-evaluated under hematological criteria for lymphoma, and vice versa. Regulators and trial designers have to think carefully about which measurement tools apply, especially for drugs being tested across both solid tumors and blood cancers.
CAR-T Therapy and Why the Distinction Keeps Mattering
Perhaps nowhere is lymphoma’s blood-cancer identity more consequential than in the newer immunotherapies. CAR-T cell therapy, in which a patient’s own immune cells are genetically engineered to attack cancer, has achieved FDA approval for several blood cancers, including B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma.10PubMed Central. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments The therapy works well in these blood cancers partly because the target cells are accessible in the blood and lymphatic tissue, and because the engineered T cells can find their targets without having to penetrate a dense, oxygen-starved tumor mass.
Solid tumors have proven far harder for CAR-T therapy to crack. The obstacles include tumor heterogeneity, immunosuppressive microenvironments within the tumor, and difficulty getting T cells to infiltrate the mass effectively.11PubMed Central. Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors The contrast is stark: lymphoma patients can access a class of therapy that remains largely experimental for people with solid cancers. If lymphoma were categorized as a solid tumor, it would likely have been lumped in with those hard-to-treat cancers in trial design, potentially delaying access to treatments that have saved lives.
Dogs Get Lymphoma Too
An unexpected angle on lymphoma’s nature comes from veterinary oncology. Dogs develop the full spectrum of lymphoid cancers seen in humans, and these canine lymphomas retain not only similar appearances and clinical behavior but also share many of the same molecular abnormalities that drive human disease.12PubMed Central. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications This makes dogs an exceptionally useful model for studying lymphoma progression and testing new treatments, in relatively short timeframes compared to human trials. The parallels extend across both species in ways that would be unusual for most solid tumors, where animal models often fail to replicate human disease faithfully. The strong cross-species resemblance in lymphoma is thought to reflect the conserved biology of the lymphocyte itself, further underscoring that this is fundamentally a disease of blood cells, regardless of how tumor-like it may appear on a scan.
Common Misconceptions That Can Trip You Up
One widespread misunderstanding is that “blood cancer” means the cancer is always floating freely in the bloodstream. For lymphoma, that is generally not the case. Most lymphoma cells reside in lymph nodes or other tissues. Some subtypes do have a leukemic phase where malignant cells spill into the blood, blurring the line with leukemia, but the primary residence of lymphoma is in solid tissue. The “blood cancer” label refers to the cell of origin, not where the cancer physically lives.
Another misconception is that because lymphoma forms masses, it should be treated with surgery. Patients sometimes arrive at an oncologist’s office expecting the lump to be removed, as it would be for a breast or skin cancer. Hearing that surgery is not the plan can feel alarming, as though the cancer is being undertreated. In reality, the chemotherapy and immunotherapy regimens used for lymphoma are highly effective precisely because they can reach malignant cells throughout the lymphatic system, something a scalpel cannot do.
A subtler confusion arises in how insurance and hospital systems organize care. Some cancer centers separate their “solid tumor” and “hematological malignancy” programs into different buildings or clinics. A lymphoma patient sent to the hematology clinic may wonder why they are sitting alongside leukemia patients when their own cancer presents as a visible mass. The organizational structure reflects biology, not a clerical error. The treatments, monitoring protocols, and clinical trial options available in the hematology program are the ones that match lymphoma’s nature.
When the Lines Get Genuinely Blurry
There are edge cases where the solid-versus-blood distinction becomes honestly difficult. Some lymphomas, particularly certain T-cell lymphomas of the skin like mycosis fungoides, progress so slowly and remain so localized that they are managed with skin-directed therapies for years, much as a dermatologist might manage a localized skin condition. Primary central nervous system lymphoma, confined to the brain, is treated with regimens that must cross the blood-brain barrier, a challenge more reminiscent of brain tumor oncology than typical hematology. And some aggressive lymphomas present as a single large mass without widespread disease, tempting a solid-tumor approach.
In each of these cases, the treatment still reflects lymphoma’s blood-cancer biology at its core, even when practical considerations borrow techniques from the solid tumor playbook. Radiation fields may be drawn using principles originally developed for solid tumors. Chemotherapy regimens may be modified to reach sanctuary sites like the brain. But the fundamental framework remains hematological: systemic therapy aimed at a cancer of lymphocytes, not local excision of a tumor arising from organ tissue. The edges are messy, as they tend to be in medicine, but the center holds.